RecruitingNot ApplicableNCT04745221

Efficacy and Safety of Auto-FMT in Preventing aGVHD

Efficacy and Safety of Autologous Fecal Bacteria Transplantation in Preventing Acute Graft Versus Host Disease After Haploidentical Hematopoietic Stem Cell Transplantation: a Multicenter, Open, Randomized Controlled Clinical Study

Sponsor

The First Affiliated Hospital of Soochow University

Enrollment

100 participants

Start Date

Mar 1, 2021

Study Type

INTERVENTIONAL

Conditions

Graft Versus Host Disease, Acute

Summary

To evaluation the efficacy and safety of autologous fecal bacteria transplantation in preventing acute graft versus host disease after haploidentical hematopoietic stem cell transplantation. Bone marrow transplant patients were recruited.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying autologous fecal bacteria for people with graft versus host disease, acute. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERautologous fecal bacteria

autologous fecal bacteria transplantation

Locations(1)

Ye Zhao

Suzhou, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04745221

Related Trials

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

NCT0564363839 locations